JP5020967B2 - セロトニントランスポーター（ｓｅｒｔ）阻害剤 - Google Patents

セロトニントランスポーター（ｓｅｒｔ）阻害剤 Download PDF

Info

Publication number
JP5020967B2
JP5020967B2 JP2008542719A JP2008542719A JP5020967B2 JP 5020967 B2 JP5020967 B2 JP 5020967B2 JP 2008542719 A JP2008542719 A JP 2008542719A JP 2008542719 A JP2008542719 A JP 2008542719A JP 5020967 B2 JP5020967 B2 JP 5020967B2
Authority
JP
Japan
Prior art keywords
phenyl
pyrrolidine
benzyloxymethyl
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008542719A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009517435A (ja
Inventor
グルントショーバー，クリストフ
ホフマン，トルシュテン
コブレット，アンドレアス
シュニダー，パトリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2009517435A publication Critical patent/JP2009517435A/ja
Application granted granted Critical
Publication of JP5020967B2 publication Critical patent/JP5020967B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2008542719A 2005-12-01 2006-11-22 セロトニントランスポーター（ｓｅｒｔ）阻害剤 Expired - Fee Related JP5020967B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05111565.7 2005-12-01
EP05111565 2005-12-01
PCT/EP2006/068740 WO2007063009A1 (en) 2005-12-01 2006-11-22 Serotonin transporter (sert) inhibitors

Publications (2)

Publication Number Publication Date
JP2009517435A JP2009517435A (ja) 2009-04-30
JP5020967B2 true JP5020967B2 (ja) 2012-09-05

Family

ID=37686112

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008542719A Expired - Fee Related JP5020967B2 (ja) 2005-12-01 2006-11-22 セロトニントランスポーター（ｓｅｒｔ）阻害剤

Country Status (13)

Country Link
US (1) US20070129419A1 (https=)
EP (1) EP1957450B1 (https=)
JP (1) JP5020967B2 (https=)
KR (1) KR101091376B1 (https=)
CN (1) CN101316816B (https=)
AT (1) ATE434605T1 (https=)
AU (1) AU2006319244B2 (https=)
BR (1) BRPI0619154A2 (https=)
CA (1) CA2631221C (https=)
DE (1) DE602006007483D1 (https=)
ES (1) ES2326285T3 (https=)
IL (1) IL191468A (https=)
WO (1) WO2007063009A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8471040B2 (en) * 2010-10-11 2013-06-25 Theravance, Inc. Serotonin reuptake inhibitors
US20160009694A1 (en) * 2013-03-15 2016-01-14 Portola Pharmaceuticals, Inc. Cyclohexanediamine compounds and methods for their preparation
CA2949160C (en) 2014-05-15 2023-03-21 Array Biopharma Inc. 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
PT3344248T (pt) 2015-09-02 2022-06-29 Trevena Inc Compostos moduladores do recetor opioide delta contendo aza-heterocíclicos de 6 membros, composições compreendendo os mesmos e seus usos
US11225487B2 (en) 2017-02-17 2022-01-18 Trevena, Inc. 7-membered aza-heterocyclic containing δ-opioid receptor modulating compounds, methods of using and making the same
BR112019016827A2 (pt) 2017-02-17 2020-04-07 Trevena Inc compostos moduladores de receptor delta-opioide contendo aza-heterocíclico com 5 membros, métodos de uso e produção dos mesmos
BR112022016941A2 (pt) * 2020-02-25 2022-10-25 Tes Pharma S R L Compostos heterocíclicos para a modulação de nr2f6

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB0119797D0 (en) * 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
ATE374183T1 (de) * 2001-11-13 2007-10-15 Schering Corp Nk1-antagonisten
US7468437B2 (en) * 2003-09-30 2008-12-23 Merck & Co., Inc. Phenyl pyrrolidine ether tachykinin receptor antagonists
US7138423B2 (en) * 2004-07-20 2006-11-21 Bristol-Myers Squibb Company Arylpyrrolidine derivatives as NK-1 /SSRI antagonists

Also Published As

Publication number Publication date
CN101316816A (zh) 2008-12-03
JP2009517435A (ja) 2009-04-30
WO2007063009A1 (en) 2007-06-07
EP1957450A1 (en) 2008-08-20
CA2631221C (en) 2014-06-03
KR101091376B1 (ko) 2011-12-07
CN101316816B (zh) 2011-07-27
AU2006319244B2 (en) 2011-07-07
ATE434605T1 (de) 2009-07-15
EP1957450B1 (en) 2009-06-24
IL191468A (en) 2012-02-29
DE602006007483D1 (https=) 2009-08-06
US20070129419A1 (en) 2007-06-07
AU2006319244A1 (en) 2007-06-07
CA2631221A1 (en) 2007-06-07
BRPI0619154A2 (pt) 2011-09-20
ES2326285T3 (es) 2009-10-06
KR20080064200A (ko) 2008-07-08

Similar Documents

Publication Publication Date Title
US7893062B2 (en) Pyrrolidine derivatives as dual NK1/NK3 receptor antagonists
US7528136B2 (en) Prolinamide derivatives as NK3 antagonists
IL191468A (en) Serotonin transporter (sert) inhibitors, process for their preparation, medicaments containing them and use thereof in the preparation of medicaments for the treatment of anxiety and depression
EP2364295B1 (en) 3-(benzylamino)-pyrrolidine derivatives and their use as nk-3 receptor antagonists
JP2010520216A (ja) ヒスタミンｈ３受容体のモジュレーターとしてのインドールおよびベンゾチオフェン化合物
US8580821B2 (en) Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety
US7501422B2 (en) Prolinamide-tetrazole derivatives as NK3 receptor antagonists

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111121

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120612

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120613

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150622

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees